Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

The Scientific Advisory Committee on Alternative Toxicological Methods recommends as a high priority the further evaluation of three methods designed to replace or refine animal use in toxicology testing. The tests were discussed at a Nov. 30 meeting in Research Triangle Park, NC. The first test is the MCF-7 estrogenic activity cell proliferation assay for cross-laboratory validation studies, which assesses the potential endocrine disruptor activity of a substance. The second nomination goes to the BALB/c 3T3 mouse fibroblast neural red uptake test method for predicting the starting doses of chemical mixtures for acute oral toxicity testing. The third test up for further evaluation is the optimal corneal holder and vehicle for bovine corneal opacity and permeability, which is used to identify potential ocular corrosives. The studies are currently undergoing pre-screening by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods and the Interagency Coordinating Committee on the Validation of Alternative Methods...

You may also be interested in...

QUOTED. 24 February 2020. Daniel Taddeo.

Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.

Herbalife 'Just Getting Started' On Growth Following Flat 2019 At $4.9bn Net Sales

"We're a growth company, well-positioned in a global trend of nutrition that the world hasn't seen before," says co-president John Agwunobi. But the direct seller's record volume increase in 2019 didn’t translate to revenue growth as China, Mexico and Central and South America pulled down results.

US FDA Tech Modernization Plan’s Costs Uncertain

Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts